A private investment firm based in West Coast USA invests across all stages, from company formation through IPO. As an evergreen fund, the firm has invested in big name biotech companies, and is capable of making large investments with no set limit.
The firm is primarily focused on 3 areas: (1) therapeutics, (2) diagnostics, and (3) synthetic biology, but open to other sectors with groundbreaking technology.
The firm has a flexible mandate and does not have any specific company or management team requirements.
If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.
Hot Investor Mandate: Private Investment Firm Seeks Opportunities in Therapeutics, Diagnostics, Synthetic Biology, and Other Groundbreaking Technology
17 Feb- Comments Leave a Comment
- Categories Hot Mandates
Popular Topics
Listen to the Podcast
Top Posts
- Hot Investor Mandate: Early-Stage Focused Fund Invests in Seed to Series A Rounds in Digital Health and Healthtech Companies
- RESI San Diego Innovator's Pitch Challenge Winners Showcase the Future of Life Science Innovation
- Don’t Miss Out: Discover Cutting-Edge Japanese Innovations at RESI San Diego 2026
- Global Family Office BioForum at RESI Boston – Where Active Investors Connect, Collaborate, and Co-Invest
- The Needle Issue #11
- Venture Philanthropy: Fast, Disciplined, and Getting People Started
- RESI Innovators Shine in San Francisco – Winners Announced
- Hot Investor Mandate: Life Sciences Investment Fund Partnered with a Family Office Invests in Seed Stage Therapeutics, Devices, Diagnostics, Life Science Tools Technologies in USA
- Help! How to Connect When an Investor Won’t Respond
- Life Science Nation, Biocat, and Biotechgate Announce RESI Europe Barcelona 2024 - June 17th In-person | 18th & 19th Virtual
Recent Posts
- Hot Investor Mandate: Early-Stage Focused Fund Invests in Seed to Series A Rounds in Digital Health and Healthtech Companies
- Hot Investor Mandate: Private Investment Firm with Asset-Centric Approach Invests in Promising Early-Stage Therapeutics Assets
- Hot Investor Mandate: Asia-Based VC Firm Invests in Early and Growth-Stage Opportunities in Life Sciences, Open to Cross Border Investment
- Hot Investor Mandate: Pharma Corporate Venture Arm Makes Strategic Investments in Therapeutics Companies, Focusing on Pre-Clinical Stage
- RESI San Diego Innovator’s Pitch Challenge Winners Showcase the Future of Life Science Innovation
Hot Mandates
-
Hot Investor Mandate 1: Korean VC Firm with Pharma Affiliation Seeks to Invest in Early Stage Therapeutics Assets, Most Interested in Oncology and Autoimmune Disease
The firm is focused on therapeutics companies and does not invest in medical devices, diagnostics, or digital health. The firm is open to considering assets of very early stages, even those as early as lead optimization phase. The firm considers various modalities, including antibodies, small molecules, and cell therapy. Currently, the firm is not interested in gene therapy. Indication-wise, the firm is most interested in oncology and autoimmune diseases but has recently looked at fibrotic diseases and certain rare diseases as well.
-
Hot Investor Mandate 2: Hong Kong Boutique VC Firm Invests in All Kinds of Healthcare Technologies and Most Interested in Large Disease Markets of Unmet Medical Need
The firm is opportunistic across all subsectors of healthcare. Within MedTech, the firm is most interested in medical devices, artificial intelligence, robotics, and mobile health. The firm is seeking post-prototype innovations that are FDA cleared or are close to receiving clearance. Within therapeutics, the firm is interested in therapeutics for large disease markets such as oncology, neurology, and metabolic diseases. The firm is open to all modalities with a special interest in immunotherapy and cell therapy.
-
Hot Investor Mandate 3: Strategic Investment Firm of Large Pharma Invests in Early and Late Stage Therapeutics & Drug-Device Combinations, Especially Interested in Orphan and Rare Diseases
A strategic investment firm of a large global pharmaceutical makes investments ranging from $5 million to $30 million, acting either as a sole investor or within a syndicate. The firm is open to considering therapeutic opportunities globally, but only if the company is pursuing a market opportunity in the USA and is in dialogue with the US FDA.
-
Hot Investor Mandate 4: USA-Based Investment Firm Can Invest Over $10M in Innovative Medtech and Digital Health Companies Based in Texas or Southwestern USA
The firm is currently looking for new investment opportunities in enterprise software, medical devices, and the healthcare IT space. The firm will invest in 510k devices and healthcare IT companies, and it is very opportunistic in terms of indications. In the past, the firm was active in medical device companies developing dental devices, endovascular innovation devices, and women’s health devices.
-
Hot Investor Mandate 1: Global VC Firm Headquartered in Asia Invests in All Parts of Therapeutics, Medical Devices, Diagnostics, and Digital Health
A venture capital firm founded in 2005 has multiple offices throughout Asia, New York, and San Diego. The firm has closed its fifth fund in 2017 and is currently raising a sixth fund, which the firm is targeting to be the largest fund to date. The firm continues to actively seek investment opportunities across a […]





Leave a comment